Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMTSE:IAMTSE:OLYNYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.09-22.3%$0.11$0.06▼$0.47$6.61M0.76553,477 shs2.31 million shsIAMIntegrated Asset ManagementC$0.00C$1.52▼C$2.92C$75.96MN/A30,209 shs8,780 shsOLYOlympia Financial GroupC$105.65+0.3%C$104.55C$89.90▼C$112.90C$254.23M0.271,641 shs1,425 shsXLYConsumer Discretionary Select Sector SPDR Fund$202.41+0.5%$195.06$166.48▼$240.28$19.84B1.263.38 million shs2.58 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%0.00%0.00%-37.91%-78.50%IAMIntegrated Asset Management0.00%0.00%0.00%0.00%0.00%OLYOlympia Financial Group+0.33%-0.05%+0.62%-3.95%-3.95%XLYConsumer Discretionary Select Sector SPDR Fund+0.48%+0.49%+3.51%-10.27%+13.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech2.1161 of 5 stars3.50.00.00.02.21.70.6IAMIntegrated Asset ManagementN/AN/AN/AN/AN/AN/AN/AN/AOLYOlympia Financial Group3.8128 of 5 stars3.50.02.50.02.93.31.3XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$2.752,908.75% UpsideIAMIntegrated Asset Management 0.00N/AN/AN/AOLYOlympia Financial Group 3.00BuyC$143.5235.84% UpsideXLYConsumer Discretionary Select Sector SPDR Fund 2.65Moderate Buy$202.41N/ACurrent Analyst Ratings BreakdownLatest IAM, XLY, AIM, and OLY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/11/2025OLYOlympia Financial GroupFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$143.52(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$170K38.87N/AN/A$0.20 per share0.46IAMIntegrated Asset ManagementC$18.31M0.00N/A4.43C$0.67 per share0.00OLYOlympia Financial GroupC$102.64M2.48C$9.06 per share11.66C$16.72 per share6.32XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/AIAMIntegrated Asset ManagementN/AC$0.1124.91N/AN/AN/AN/AN/AN/AOLYOlympia Financial GroupC$24.45MC$10.1610.40∞N/A23.82%64.95%35.88%N/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A23.95∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AIAMIntegrated Asset ManagementC$0.114.38%N/A100.00%N/AOLYOlympia Financial GroupC$7.206.81%N/A70.86%N/AXLYConsumer Discretionary Select Sector SPDR Fund$1.770.87%N/AN/AN/ALatest IAM, XLY, AIM, and OLY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/21/2025OLYOlympia Financial GroupMonthlyC$0.606.99%5/21/20255/30/20255/30/20254/17/2025OLYOlympia Financial GroupMonthlyC$0.606.94%4/17/20254/30/20254/30/20253/20/2025OLYOlympia Financial GroupMonthlyC$0.606.83%3/20/20253/31/20253/31/20252/19/2025OLYOlympia Financial GroupMonthlyC$0.606.66%2/19/20252/28/20252/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75IAMIntegrated Asset ManagementN/A4.854.81OLYOlympia Financial Group6.003.321.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%IAMIntegrated Asset ManagementN/AOLYOlympia Financial Group1.17%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%IAMIntegrated Asset ManagementN/AOLYOlympia Financial Group34.63%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2072.29 million68.74 millionNot OptionableIAMIntegrated Asset Management5627.72 millionN/ANot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionableXLYConsumer Discretionary Select Sector SPDR Fund147,00098.00 millionN/ANot OptionableIAM, XLY, AIM, and OLY HeadlinesRecent News About These CompaniesOil Slumps to Below $60: ETFs to GainMay 5, 2025 | zacks.comWeekly Economic Snapshot: Solid Jobs Amid GDP Contraction & Crashing ConfidenceMay 5, 2025 | etftrends.com7 of 17 S&P 500 consumer discretionary stocks beat estimates - Earnings ScoreboardMay 4, 2025 | msn.comPCE Report Preview: TLT, Sector ETFs in FocusApril 29, 2025 | finance.yahoo.comIs Weak Consumer Sentiment Hurting Discretionary ETFs?April 28, 2025 | zacks.comWeekly Economic Snapshot: Housing Divide Amid Plunging SentimentApril 28, 2025 | etftrends.comConsumer Stock Winners And Losers — Has Retail Sentiment Shifted After Volatile Week?April 21, 2025 | msn.comMost and least shorted S&P 500 consumer discretionary stocks in MarchApril 19, 2025 | msn.comHow To Invest In Different Sectors Of The Stock MarketApril 14, 2025 | news24online.comWeekly Economic Snapshot: Tariff Swings, Inflation Relief in the Rearview, & Sinking SentimentApril 14, 2025 | etftrends.comTaking Apart the Tariff Impact With ETFsApril 10, 2025 | etftrends.comTaking Apart the Tariff Impact With ETFsApril 10, 2025 | etftrends.comETF Prime: Islam Analyzes Tariffs Impact on ETFsApril 8, 2025 | etftrends.comDiagnosing the Market on Health Day: 6 ETFs Looking HealthyApril 7, 2025 | zacks.comTop consumer discretionary gainers and losers during tariff frenzy weekApril 6, 2025 | msn.comTech and consumer discretionary stocks are getting hit especially hardApril 3, 2025 | marketwatch.comShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?April 2, 2025 | zacks.comWeekly Economic Snapshot: Consumer Fears & Inflation Drag Down MarketsMarch 31, 2025 | etftrends.comDomino's Pizza Stock: Is DPZ Outperforming the Consumer Cyclical Sector?March 26, 2025 | msn.comWeekly Economic Snapshot: Inflation Relief Tempered by Sentiment ConcernsMarch 17, 2025 | etftrends.com3 Stocks Institutions Are Quietly Dumping (XLY)March 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitIAMGOLD Stock Climbs as Turnaround Story Gains TractionBy Jeffrey Neal Johnson | April 11, 2025View IAMGOLD Stock Climbs as Turnaround Story Gains TractionIBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthIAM, XLY, AIM, and OLY Company DescriptionsAIM ImmunoTech NYSE:AIM$0.09 -0.03 (-22.34%) As of 04/4/2025 This is a fair market value price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Integrated Asset Management TSE:IAMIntegrated Asset Management Corp. operates as an alternative asset investment management company. The company provides investors with private equity, private corporate debt, managed futures, hedge funds, real estate investment management, property management and leasing, and merchant banking. It offers alternative asset class management to institutional, pension, and private clients. Integrated Asset Management Corp. was founded in 1998 and is headquartered in Toronto, Canada.Olympia Financial Group TSE:OLYC$105.65 +0.35 (+0.33%) As of 05/9/2025 01:48 PM EasternOlympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$202.41 +0.97 (+0.48%) As of 05/9/2025 04:10 PM EasternConsumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
